BGB-A445 + tislelizumab + chemotherapy

This is a combination regimen consisting of **BGB-A445** (a humanized IgG1 monoclonal antibody agonist of OX40), **tislelizumab** (a humanized IgG4 anti-PD-1 monoclonal antibody), and standard **chemotherapy** (agents such as cisplatin, gemcitabine, or docetaxel—exact chemotherapy varies by trial). BGB-A445 activates OX40 (TNFRSF4) on T cells, promoting T cell survival, proliferation, and depleting regulatory T cells via ADCC. Tislelizumab blocks the PD-1 immune checkpoint, enhancing T cell antitumor activity. The regimen is under investigation for advanced solid tumors, especially nasopharyngeal carcinoma (NPC), non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). It is being developed and studied primarily by BeiGene. Early clinical data show the triple regimen is generally well tolerated and has preliminary antitumor activity, particularly in advanced NPC, NSCLC, and HNSCC.[1][3][8]

Other names

gimistotug + tislelizumab + chemotherapy